Eli Lilly is paying as much as $300 million for CrossBridge Bio, a startup growing antibody drug conjugates that ship two drug payloads to cancers. Past doubtlessly higher efficacy, CrossBio’s twin strategy may additionally combat drug resistance.
The submit Eli Lilly Buys Startup CrossBridge Bio to Carry a Extra Highly effective Strike to Tumors appeared first on MedCity Information.
